Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1987 Dec;56(6):709–713. doi: 10.1038/bjc.1987.275

Human monoclonal antibodies and monoclonal antibody multispecificity.

A M Campbell 1, P Whitford 1, R E Leake 1
PMCID: PMC2002384  PMID: 3325093

Abstract

The majority of human anti-tumour monoclonal antibodies (Mabs) isolated to date have been disappointing. Firstly, they react or cross react with intracellular cytoskeletal proteins or nuclear antigens and therefore are of limited value as blood borne agents. They are also generally of the IgM isotype and show relatively low intrinsic affinity for the primary epitope. Secondly, such Mabs can be generated from normal, non tumour bearing subjects at a frequency comparable to their production from tumour patients. This latter observation is true also for common autoantigens such as DNA and IgG since Mabs to these can also be generated from normal subjects in addition to autoimmune individuals. This article rationalises these observations in the context of the requirement for clinical use for human Mabs. It discusses the evidence that there is a potentially useful B cell response to be immortalised, and examines the consequences of the newly recognised phenomenon of monoclonal antibody multispecificity both on the methodology of their generation and on their subsequent use as imaging and therapeutic tools.

Full text

PDF
709

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams P. G., Rossio J. L., Stevenson H. C., Foon K. A. Optimal strategies for developing human-human monoclonal antibodies. Methods Enzymol. 1986;121:107–119. doi: 10.1016/0076-6879(86)21012-5. [DOI] [PubMed] [Google Scholar]
  2. Baldwin R. W., Byers V. S. Monoclonal antibodies in cancer treatment. Lancet. 1986 Mar 15;1(8481):603–605. doi: 10.1016/s0140-6736(86)92821-7. [DOI] [PubMed] [Google Scholar]
  3. Campbell A. M., McCormack M. A., Ross C. A., Leake R. E. Immunological analysis of the specificity of the autologous humoral response in breast cancer patients. Br J Cancer. 1986 Jan;53(1):7–11. doi: 10.1038/bjc.1986.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cobb L. M., Humm J. L. Radioimmunotherapy of malignancy using antibody targeted radionuclides. Br J Cancer. 1986 Dec;54(6):863–870. doi: 10.1038/bjc.1986.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cote R. J., Morrissey D. M., Houghton A. N., Thomson T. M., Daly M. E., Oettgen H. F., Old L. J. Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens. Proc Natl Acad Sci U S A. 1986 May;83(9):2959–2963. doi: 10.1073/pnas.83.9.2959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eilat D. Anti-DNA antibodies: problems in their study and interpretation. Clin Exp Immunol. 1986 Aug;65(2):215–222. [PMC free article] [PubMed] [Google Scholar]
  7. Ghosh S., Campbell A. M. Assay dependent specificities of monoclonal antibodies to bacterial antigens. Clin Exp Immunol. 1986 Aug;65(2):443–449. [PMC free article] [PubMed] [Google Scholar]
  8. Greaves M. F. "Target" cells, cellular phenotypes, and lineage fidelity in human leukaemia. J Cell Physiol Suppl. 1982;1:113–125. doi: 10.1002/jcp.1041130418. [DOI] [PubMed] [Google Scholar]
  9. Klein G., Klein E. Evolution of tumours and the impact of molecular oncology. Nature. 1985 May 16;315(6016):190–195. doi: 10.1038/315190a0. [DOI] [PubMed] [Google Scholar]
  10. Kozbor D., Roder J. C., Sierzega M. E., Cole S. P., Croce C. M. Comparative phenotypic analysis of available human hybridoma fusion partners. Methods Enzymol. 1986;121:120–140. doi: 10.1016/0076-6879(86)21013-7. [DOI] [PubMed] [Google Scholar]
  11. Miller R. A., Maloney D. G., Warnke R., Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982 Mar 4;306(9):517–522. doi: 10.1056/NEJM198203043060906. [DOI] [PubMed] [Google Scholar]
  12. Poste G. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies. Cancer Treat Rep. 1986 Jan;70(1):183–199. [PubMed] [Google Scholar]
  13. Roder J. C., Cole S. P., Kozbor D. The EBV-hybridoma technique. Methods Enzymol. 1986;121:140–167. doi: 10.1016/0076-6879(86)21014-9. [DOI] [PubMed] [Google Scholar]
  14. Sahagan B. G., Dorai H., Saltzgaber-Muller J., Toneguzzo F., Guindon C. A., Lilly S. P., McDonald K. W., Morrissey D. V., Stone B. A., Davis G. L. A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen. J Immunol. 1986 Aug 1;137(3):1066–1074. [PubMed] [Google Scholar]
  15. Stollar B. D., Zon G., Pastor R. W. A recognition site on synthetic helical oligonucleotides for monoclonal anti-native DNA autoantibody. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4469–4473. doi: 10.1073/pnas.83.12.4469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Vaughan A. T., Bradwell A. R., Dykes P. W., Anderson P. Illusions of tumour killing using radiolabelled antibodies. Lancet. 1986 Jun 28;1(8496):1492–1493. doi: 10.1016/s0140-6736(86)91520-5. [DOI] [PubMed] [Google Scholar]
  17. Winger L., Winger C., Shastry P., Russell A., Longenecker M. Efficient generation in vitro, from human peripheral blood cells, of monoclonal Epstein-Barr virus transformants producing specific antibody to a variety of antigens without prior deliberate immunization. Proc Natl Acad Sci U S A. 1983 Jul;80(14):4484–4488. doi: 10.1073/pnas.80.14.4484. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES